# OncLive > OncLive - Healthcare Publication - Base URL: https://www.onclive.com - Generated: 2026-10-18T21:16:20.733Z - Content updates: multiple times daily ## Content Access for AI Agents This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML. **Supported content types:** - `text/markdown` — Clean Markdown with YAML frontmatter - `text/plain` — Plain text (same as Markdown) - `text/html` — Default HTML response **Example request:** ``` curl -H "Accept: text/markdown" https://www.onclive.com/view/article-slug ``` **YAML frontmatter schema** (returned with every Markdown response): | Field | Type | Description | |-------|------|-------------| | `title` | string | Article headline | | `description` | string | Summary/excerpt (max 300 chars) | | `url` | string | Canonical article URL | | `canonical_url` | string | Canonical URL if different from `url` | | `published` | ISO 8601 | Original publication date | | `modified` | ISO 8601 | Last modification date | | `authors` | string[] | Author display names | | `content_type` | string | Content category (e.g., "News", "Clinical") | | `categories` | string[] | Taxonomy categories | | `tags` | string[] | SEO tags | | `image` | string | Featured image URL | | `publisher` | string | Publication/site name | **Discovery headers** (included on all responses): - `Link: ; rel="llms"` — RFC 8288 link to this file - `X-Llms-Txt: https://www.onclive.com/llms.txt` — Explicit discovery header ## Usage Policy - Robots policy: [https://www.onclive.com/robots.txt](https://www.onclive.com/robots.txt) - Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329) - Rate guidance: prefer RSS and sitemap feeds over crawling individual pages - Attribution: All content © MJH Life Sciences. Include source URLs when citing. ## Content Categories - [Blood Club](https://www.onclive.com/blood-club) - [Breaking News](https://www.onclive.com/breaking-news) - [COVID-19](https://www.onclive.com/covid-19) - [Clinical](https://www.onclive.com/clinical) - [Clinical Trials in Focus](https://www.onclive.com//clinical-trials-in-focus) - [Conference](https://www.onclive.com/conference) - [Emerging Biomarker](https://www.onclive.com/emerging-biomarker) - [Events](https://www.onclive.com/events) - [Exhibitor](https://www.onclive.com/exhibitor) - [Immunotherapy in GU Cancers](https://www.onclive.com/immunotherapy-in-gu-cancers) - [Immunotherapy in Lung Cancer](https://www.onclive.com/immunotherapy-in-lung-cancer) - [Immunotherapy in Melanoma](https://www.onclive.com/immunotherapy-in-melanoma) - [Insights](https://www.onclive.com/insights) - [Insights Video Series](https://www.onclive.com/insights-video-series) - [Leukemia Experts Reflect on Defining Moments, Career Experiences, and Gender Bias as Women in the Field](https://www.onclive.com/leukemia-experts-reflect-on-defining-moments-career-experiences-and-gender-bias-as-women-in-the-field) - [Medical Content](https://www.onclive.com/medical-content) - [NO ADS](https://www.onclive.com/noads) - [National Fellows Forum](https://www.onclive.com/national-fellows-forum) - [News](https://www.onclive.com/news) - [Onc App Featured Content](https://www.onclive.com/app-featured-content) - [OncClub](https://www.onclive.com/oncclub) - [OncLive News Network®](https://www.onclive.com/news-network) - [OncLive Peer Exchange® ](https://www.onclive.com/peer-exchange) - [OncLive TV](https://www.onclive.com/onclive-tv) - [Oncology Nursing News](https://www.onclive.com/nurses) - [Podcasts](https://www.onclive.com/podcasts) - [Publications](https://www.onclive.com/publications) - [Rapid Readouts](https://www.onclive.com/rapid-readouts) - [Scientific Interchange & Workshop](https://www.onclive.com/scientific-interchange-and-workshop) - [Special Reports in Personalized Cancer Care](https://www.onclive.com/personalized-medicine) - [Sponsored](https://www.onclive.com/sponsored) - [The Talk](https://www.onclive.com/the-talk) - [Thoracic Night Live](https://www.onclive.com/thoracic-night-live) - [Video Series](https://www.onclive.com/video-series) - [Webinars](https://www.onclive.com/webinars) ## Featured Content - [Five Under 5: Top Oncology Videos for the Week of 10/12](https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-10-12): The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs. - [Early-Phase INCA33890 Data Lay the Foundation for Phase 3 Combination Research in MSS CRC](https://www.onclive.com/view/early-phase-inca33890-data-lay-the-foundation-for-phase-3-combination-research-in-mss-crc): Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer... - [The OncFive: Top Oncology Articles for the Week of 10/11](https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-10-11): The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more. - [Alternative Cemiplimab Dosing Strategy Receives CHMP Recommendation in Multiple Cancer Types](https://www.onclive.com/view/cemiplimab-receives-chmp-recommendation-in-multiple-cancer-types): The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months. - [FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer](https://www.onclive.com/view/fda-approval-insights-first-line-maintenance-tucatinib-trastuzumab-pertuzumab-in-advanced-her2-breast-cancer): Dr Hamilton discusses the FDA approval of tucatinib/trastuzumab/pertuzumab maintenance for unresectable, locally advanced HER2-positive breast cancer. - [VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026 ](https://www.onclive.com/view/volga-dasl-hicap-data-highlight-key-genitourinary-cancer-presentations-arriving-at-esmo-2026): Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress. - [Neoadjuvant NAUTIKA1 Data, Broad Molecular Profiling, and Clinical Pearls](https://www.onclive.com/view/neoadjuvant-nautika1-data-broad-molecular-profiling-and-clinical-pearls): New lung cancer studies weigh EGFR regimen intensification against improved supportive care, while experts spotlight leptomeningeal testing advances a... - [ First-Line Data From AMIGO-1 and COPERNICUS, EGFR Result in Central Nervous System Involvement, and KRAS G12C in Practice](https://www.onclive.com/view/first-line-data-from-amigo-1-and-copernicus-egfr-result-in-central-nervous-system-involvement-and-kras-g12c-in-practice): Experts weigh new lung cancer trial strategies, balancing stronger EGFR regimens against safer delivery, plus advances in leptomeningeal diagnosis and... - [ The EGFR Result at Progression and the Updated HARMONi Overall Survival Analysis](https://www.onclive.com/view/the-egfr-result-at-progression-and-the-updated-harmoni-overall-survival-analysis): After EGFR TKI progression, clinicians reassess biopsy and NGS for resistance drivers and weigh emerging survival data for ivonesmab plus chemotherapy... - [Large-Scale Study Advances Detection of DNA Mutations Across the Human Genome ](https://www.onclive.com/view/large-scale-study-advances-detection-of-dna-mutations-across-the-human-genome): Researchers in a Mayo Clinic-led study have shown how to detect a broad range of DNA mutations in noncancerous human tissues and across the genome. ## Feeds and Indexes - [RSS Feed](https://www.onclive.com/rss.xml): Latest articles in XML syndication format - [Sitemap](https://www.onclive.com/sitemap.xml): Complete URL index for all published pages - [News Sitemap](https://www.onclive.com/sitemap-news.xml): Recent articles optimized for news indexing - [Authors Directory](https://www.onclive.com/authors): Browse all contributors and their published work